The world’s first human trial of a drug that can regenerate teeth will begin in a few months, less than a year on from news of its success in animals.
This paves the way for the medicine to be commercially available as early as 2030.
The trial, which will take place at Kyoto University Hospital from September to August 2025, will treat 30 males aged 30-64 who are missing at least one molar.
The intravenous treatment will be tested for its efficacy on human dentition, after it successfully grew new teeth in ferret and mouse models with no significant side effects.
“We want to do something to help those who are suffering from tooth loss or absence,” said lead researcher Katsu Takahashi, head of dentistry and oral surgery at Kitano Hospital.
Israel says it’s taken control of key area of Gaza’s border with Egypt full of smuggling tunnels
“While there has been no treatment to date providing a permanent cure, we feel that people’s expectations for tooth growth are high.”
Following this 11-month first stage, the researchers will then trial the drug on patients aged 2-7 who are missing at least four teeth due to congenital tooth deficiency, which is estimated to affect 1% of people.
The team is recruiting for this Phase IIa trial now.
Continue here: New Atlas
Ask me anything
Explore related questions
